NEW YORK, July 30, 2015 /PRNewswire/ --
36Equity Research Institute has initiated coverage on the
following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Endo
International PLC (NASDAQ: ENDP), Amarin Corporation PLC (NASDAQ:
AMRN), United Therapeutics Corporation (NASDAQ: UTHR), and POZEN
Inc. (NASDAQ: POZN). Free research report on Isis Pharma can be
accessed at
https://www.EquityResearchInstitute.com/reports?keyword=ISIS On
Wednesday, July 29, 2015, the NASDAQ
Composite ended at 5,111.73, up 0.44%, the Dow Jones Industrial
Average advanced 0.69%, to finish the day at 17,751.39, and the
S&P 500 closed at 2,108.57, up 0.73%. The gains were broad
based as eight out of nine sectors ended the session in positive.
Register for your complimentary reports at the links given below.
Isis Pharmaceuticals Inc.'s stock lost 2.48%, to close the day
at $53.05. The stock recorded a
trading volume of 1.85 million shares, below its three months
average volume of 2.37 million shares. Over the last one month and
over the past three months, Isis Pharmaceuticals Inc.'s shares have
fallen by 5.35% and 10.55%, respectively. Furthermore, the stock
has lost 14.08% since the start of this year. The company's shares
are trading 12.18% below their 200-day moving average.
Additionally, Isis Pharmaceuticals Inc. has a Relative Strength
Index (RSI) of 35.93. Sign up and read the free notes on ISIS
at:
https://www.EquityResearchInstitute.com/reports?keyword=ISIS
On Wednesday, shares in Endo International PLC recorded a
trading volume of 1.31 million shares, lower than their three
months average volume of 2.29 million shares. The stock ended the
day 1.64% lower at $86.19. Although,
Endo International PLC's stock has lost 0.40% in the previous three
months, it has advanced 9.95% in the last one month and 19.51% on
YTD basis. The company is trading above its 50-day and 200-day
moving averages by 3.50% and 7.46%, respectively. Furthermore,
shares of Endo International PLC have an RSI of 56.24. The
complimentary notes on ENDP can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=ENDP
Amarin Corp. PLC's stock gained 1.40%, to close Wednesday's
session at $2.18. The stock recorded
a trading volume of 0.59 million shares, below its three months
average volume of 1.97 million shares. Over the previous three
months and since the beginning of 2015, Amarin Corp. PLC's shares
have advanced 5.31% and 122.52%, respectively. However, the stock
has declined 5.63% in the last one month. The company is trading
28.49% above its 200-day moving average. Furthermore, Amarin Corp.
PLC's stock has an RSI of 38.93. Register for free on Equity
Research Institute and access the latest research on AMRN at:
https://www.EquityResearchInstitute.com/reports?keyword=AMRN
United Therapeutics Corp.'s stock finished Wednesday's session
0.74% higher at $167.18. A total of
0.71 million shares were traded, which was above its three months
average volume of 0.62 million shares. Over the previous three
months and since the start of this year, United Therapeutics
Corp.'s shares have gained 1.51% and 29.11%, respectively. However,
the stock has fallen by 2.09% in the last one month. The company's
shares are trading above their 200-day moving average by 7.01%.
United Therapeutics Corp.'s stock traded at a PE ratio of 49.46 and
has an RSI of 37.76. The complete research on UTHR is available for
free at:
https://www.EquityResearchInstitute.com/reports?keyword=UTHR
On Wednesday, shares in POZEN Inc. ended the session 3.90% lower
at $11.69. The stock reported a
trading volume of 0.52 million shares, below its three months
average volume of 0.67 million shares. Shares of the company traded
at a PE ratio of 23.39. POZEN Inc.'s shares have surged 11.91% in
the last one month, 45.28% in the previous three months and 46.19%
on YTD basis. The stock is trading 21.23% above its 50-day moving
average and 40.29% above its 200-day moving average. Moreover,
shares of POZEN Inc. have an RSI of 62.19. Free in-depth research
on POZN is available at:
https://www.EquityResearchInstitute.com/reports?keyword=POZN
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com